The Plasma Cell Disorder Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures plasma cell disorder (PCD) post-HCT data such as: disease assessment at the time of best response, hematologic and organ parameters at the time of best response, post-HCT therapy, disease status at the time of evaluation for this reporting period, and current status of amyloidosis for this reporting period.

This form must be completed for all recipients whose primary disease reported on the Pre-TED Disease Classification Form (Form 2402) is “Multiple myeloma/plasma cell disorder (PCD).” The Post-HCT Plasma Cell Disorder form must be completed in conjunction with each Post-HCT follow-up form (Form 2100). This form is designed to capture specific data occurring within the timeframe of each reporting period (i.e., between day 0 and day 100; between day 100 and the six-month date of contact for six-month follow-up; and between the date of contact for the six-month follow-up and the date of contact for the one-year follow-up, etc.).

Links to Sections of the Form
Q1-2: Disease Specificity
Q3-53: Disease Assessment at the Time of Best Response to HCT or Cellular Therapy
Q54-109: Organ Parameters of Amyloidosis at the Time of Best Response
Q110-141: POEMS Syndrome Assessment at the Time of Best Response
Q142-210: Post-Infusion Therapy
Q211-252: Disease Status at the Time of Evaluation for this Reporting Period
Q253-311: Current Status of Amyloidosis for this Reporting Period
Q312-343: Current Status of POEMS Syndrome for this Reporting Period

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please click here or reference the retired manual section on the Retired Forms Manuals webpage.

Date Manual Section Add/Remove/Modify Description
10/23/2020 2116: PCD Post-Infusion Modify Provided clarification and additional examples on how to report next generation flow (NGF) in questions 39-42.
10/1/2020 2116: PCD Post-Infusion Add Instructions added on when to use the “unknown” and “not applicable” options for question 190: Indicate if the recipient received maintenance therapy after treatment for relapse / progression since the date of the last report. If “yes,” continue with question 191. If “no,” continue with question 211. If it is not known or not possible to determine if the recipient was placed on subsequent maintenance therapy after treatment for relapse / progression, then select “Unknown” and proceed to question 211. This option should be used sparingly and only in cases when it is truly unknown as to whether maintenance therapy was given within the reporting period after treatment for relapse / progression. Indicate “Not Applicable” if the recipient did not receive treatment for relapse / progression. Please see the example below: Example: A recipient was in CR and was receiving maintenance Revlimid. Due to health issues, the maintenance therapy was briefly discontinued; however, the recipient’s IgG reappeared during this time. The patient was not treated for relapse and eventually continued on with the Revlimid maintenance. In this case, question 190 would be answered as “Not Applicable” because he was not treated for relapse but instead continued on with his maintenance therapy.
6/9/2020 2116: PCD Post-Infusion Modify Update question 2 with the correct instructions: Indicate if the recipient had a concurrent or preceding plasma cell disorder. Many recipients progress to symptomatic myeloma from a preceding condition or have a concurrent plasma cell disorder, such as amyloidosis. This question will be auto-populated from the Plasma Cell Disorders (PCD) Pre-Infusion (2016) Disease Classification (2402) Form.
5/8/2020 2116: PCD Post-Infusion Add Added guidance to questions 124-125 to document unit of measure to the nearest tenth.
5/8/2020 2116: PCD Post-Infusion Add Added guidance to questions 329-330 to document unit of measure to the nearest tenth.
5/8/2020 2116: PCD Post-Infusion Add Added guidance to questions 326-327 to document unit of measure to the nearest tenth.
5/8/2020 2116: PCD Post-Infusion Add Added guidance to questions 127-128 to document unit of measure to the nearest tenth.
3/27/2020 2116: PCD Post-Infusion Modify Updated question numbers found in guidance for answering questions 54 and 91 in the section Q54-109: Organ Parameters of Amyloidosis at the Time of Best Response.
3/27/2020 2116: PCD Post-Infusion Modify Updated question numbers found in guidance for answering questions 256 and 293 in the section Q253-311: Current Status of Amyloidosis for this Reporting Period.
3/27/2020 2116: PCD Post-Infusion Add Added sentence for guidance on answering question 251 in that says This question will not be enabled if the primary disease for transplant is monoclonal gammopathy of renal significance (MGRS). in the section Q211-252: Disease Status at the Time of Evaluation for this Reporting Period.
3/27/2020 2116: PCD Post-Infusion Add Added sentence for guidance on answering question 3 in that says This question will not be enabled if the primary disease for transplant is monoclonal gammopathy of renal significance (MGRS). in the section Q3-53: Disease Assessment at the Time of Best Response to HCT or Cellular Therapy.
3/23/2020 2116: PCD Post-Infusion Add Added information about the LV strain percentage in the Q253-311: Current Status pf Amyloidosis for this Reporting Period section for questions 265-266.
3/23/2020 2116: PCD Post-Infusion Add Added information about the LV strain percentage in the Q54-109: Organ Parameters of Amyloidosis at the Time of Best Response section for questions 63-64.
1/24/2020 2116: PCD Post-Infusion Modify Version 3 of the 2016: Plasma Cell Disorders (PCD) Post-Infusion Data section of the Forms Instruction Manual released. Version 3 corresponds to revision 4 of the Form 2116.
Last modified: Nov 11, 2020

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.